bermelanotide

Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
Tue, 10/4/16 - 10:07 am
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals